Search results
Results from the WOW.Com Content Network
Print/export Download as PDF; Printable version; In other projects ... Pages in category "Osteoporosis drugs" The following 5 pages are in this category, out of 5 ...
Consequently, these drugs have been researched for the treatment of osteoporosis, [2] [3] [4] though with only limited success. [5] More recent research has suggested a number of additional applications for these drugs, such as hyperresponsiveness and inflammation in allergic asthma. [6] [7] [8] [9]
Bisphosphonates are used to treat osteoporosis, osteitis deformans (Paget's disease of the bone), bone metastasis (with or without hypercalcemia), multiple myeloma, and other conditions involving fragile, breakable bone. In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate.
SERMs that have not been approved for medical use include arzoxifene, brilanestrant, clomifenoxide (clomiphene N-oxide; metabolite of clomifene), [3] droloxifene (3-hydroxytamoxifen), etacstil, fispemifene, GW-7604 (4-hydroxyetacstil; metabolite of etacstil), idoxifene (pyrrolidino-4-iodotamoxifen), levormeloxifene ((L)-ormeloxifene), miproxifene, nafoxidine, nitromifene (CI-628), NNC 45-0095 ...
Chemical structure of bisphosphonates. Bisphosphonates are an important class of drugs originally commercialised in the mid to late 20th century. They are used for the treatment of osteoporosis and other bone disorders that cause bone fragility and diseases where bone resorption is excessive.
For premium support please call: 800-290-4726 more ways to reach us
Pharmaceutical giant Merck (NYS: MRK) reported promising results from a phase II drug trial for its new osteoporosis drug, odanacatib. Merck plans to submit applications for the drug to U.S ...
For premium support please call: 800-290-4726 more ways to reach us